KAS
LCTX icon

Kestra Advisory Services’s Lineage Cell Therapeutics LCTX Stock Holding History

Kestra Advisory Services’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44K Buy
27,847
+100
+0.4% +$169 ﹤0.01% 3065
2025
Q4 		$46.3K Buy
27,747
+17,647
+175% +$30.5K ﹤0.01% 3994
2025
Q3 		$17.1K Buy
+10,100
New +$12K ﹤0.01% 2886

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kestra Advisory Services's LCTX Position: Q1 2026 in Review

Kestra Advisory Services increased its Lineage Cell Therapeutics (LCTX) stake by 0.36% in Q1 2026, buying an estimated $169 and bringing the position to 27,847 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #3065.

Kestra Advisory Services first reported a position in LCTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $46.3K in Q4 2025. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Kestra Advisory Services held 27,847 shares of Lineage Cell Therapeutics worth $44K as of Q1 2026.
  • Kestra Advisory Services bought 100 Lineage Cell Therapeutics shares in Q1 2026, an estimated $169.
  • Lineage Cell Therapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q1 2026, its #3065 holding.
  • Kestra Advisory Services first reported a position in Lineage Cell Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Kestra Advisory Services's Lineage Cell Therapeutics position peaked at $46.3K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.